UAB 1326: A Phase II Study of Neratinib Alone and in Combination with Fulvestrant in Metastatic HER2 Non-Amplified but HER2 Mutant Breast Cancer

Grant

Awarded By

Total Award Amount

  • 46700.00
  • Direct Costs

  • 37063.00
  • Sponsor Award Id

  • Contributor

  • Gabrielle Rocque M.D.   Investigator  
  • Lisle Nabell M.D.   Investigator